SCHEMBL24257622

SCHEMBL24257622

COc1c(C#N)ncc(-c2ccn(-c3ccccc3)c2)c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.37
TUBB4A P04350 5/20 0.36
TUBB P07437 5/20 0.36
TUBA3C P0DPH7 5/20 0.36
TUBA1B P68363 5/20 0.36
TUBA4A P68366 5/20 0.36
TUBB4B P68371 5/20 0.36
TUBB3 Q13509 5/20 0.36
TUBB2A Q13885 5/20 0.36
TUBB8 Q3ZCM7 5/20 0.36
TUBA3E Q6PEY2 5/20 0.36
TUBA1A Q71U36 5/20 0.36
TUBA1C Q9BQE3 5/20 0.36
TUBB6 Q9BUF5 5/20 0.36
TUBB2B Q9BVA1 5/20 0.36
TUBB1 Q9H4B7 5/20 0.36
HPGD P15428 3/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257577 0.79 TUBB4A (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24257859 0.72 EGLN1 (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24257678 0.69 GRM4 (0.50) RAB9AALDH1A1KDM4EMAPTTSHR
SCHEMBL24257761 0.67 CNR2 (0.40) HPGDALDH1A1KDM4EMAPTTSHR
SCHEMBL24257758 0.67 POLB (0.41) RAB9ANPC1ALDH1A1MAPTLMNA
SCHEMBL24257703 0.67 ALDH1A1 (0.37) HPGDALDH1A1KDM4EMAPTTDP1
SCHEMBL7807352 0.67 TUBB4A (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL26260178 0.66 AGXT (0.39) HPGDALDH1A1KDM4E
SCHEMBL24257562 0.65 MAOB (0.47) HPGDALDH1A1HSD17B10MAPTTSHR
SCHEMBL30546831 0.65 MAOB (0.47) HPGDALDH1A1HSD17B10MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 GRM5 1946/4885TUBB4A 2918/4885TUBB 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.